FDA advisory committee recommends approval of simeprevir for combination treatment of genotype 1 chronic hepatitis C in adult patients
Janssen Research & Development, LLC (Janssen) announced today that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted unanimously (19 to 0) to recommend approval of the investigational protease inhibitor simeprevir (TMC435) administered once daily as a 150 mg capsule with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including cirrhosis...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Liver Disease / Hepatitis Source Type: news
More News: Cirrhosis | Food and Drug Administration (FDA) | Health | Hepatitis | Hepatitis C | Liver | Liver Disease | Urology & Nephrology